Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

As the interest in active surveillance continues to grow, the question becomes choosing patients who are the best candidates, explains Febbo. GPS will help choose who is the right patient to go on active surveillance.

If a patient goes on active surveillance they receive a score to determine their individualized risk of having aggressive disease.

Videos

Dr. Febbo on the Impact of Oncotype DX Genetic Prostate Score 

Phil Febbo, MD, chief medical officer, Genomic Health, explains the Oncotype DX Genomic Prostate Score (GPS) for patients with clinically low-risk prostate cancer.

The Oncotype DX GPS was developed to predict disease aggressiveness to aid in the decision of whether a patient undergoes active surveillance or definitive treatment, says Febbo.

Results from a clinical validation study, conducted in collaboration with Kaiser Permanente Northern California, showed that this test is a strong predictor of biochemical recurrence and rise in prostate-specific antigen (PSA) in patients following surgery.

As of Feburary 2017, 22 clinical trials involving more than 4200 patients with prostate cancer have been conducted.

Phil Febbo, MD

Articles

Dr. Febbo on the Impact of Oncotype DX Genetic Prostate Score

Dr. Febbo Explains the Oncotype DX Genomic Prostate Score